TO THE EDITOR
In B-cell tumors, accurate assessment of somatic mutational status has implications for defining tumor origin and, in some categories, has relevance for predicting the clinical outcome. In 1999, it was found that in chronic lymphocytic leukemia (CLL) cases carrying V H -genes with 498% homology to the closest germline (GL) gene identified a subset with a poorer prognosis, as compared to cases which had clearly undergone somatic mutation. 1 Initially, the 98% cutoff was used to exclude potential polymorphic variant sequences. It was a short cut to avoid analyzing the corresponding GL gene in each patient, and is now used for assignment of mutational status in a range of B-cell tumors.
The most integrated V-base database (http://www.mrc-cpe. cam.ac.uk/vbase) describes 47 polymorphisms in 30/51 functional V H -gene segments, with nucleotide differences from GL generally of o1%, and only five less frequently used V H segments, V 1-03 , V 1-69 , V 3-13 , V 4-28 and V 4-b , with 42% variation. Aligned V H -genes readily map to the correct allele, and the 98% cutoff point seemed reasonable. However, low levels of mutations can occur in V H -genes and single-base changes (0.33-0.35% from germ line) may be important for improving the antigen recognition. 2 It is possible therefore that significant changes could be occurring in cases with apparent 498% homology to GL. While it is unlikely to affect the prognostic power in CLL, it has implications for our understanding of the behavior of B-cell tumors.
One problem with assessing low levels of mutation is that of the approaching Taq error rate, and, although an increased rate may suggest somatic mutation, it can still be questioned. An indicator of the reality of base changes is identification of the same change in 41 sequence derived from separate amplification reactions. However, this parameter applies mainly to mutations occurring early in tumor development, and may not be evident from those accumulating late in the life of the clone. It has revealed genuine intraclonal heterogeneity in some cases of monoclonal gammopathy of undetermined significance, distinguishing it from the more malignant counterpart, multiple myeloma. 3 For B-cell tumors with a low level (o2%) of somatic mutation, this approach has not generally been applied, since there is no obvious clinical reason for investigation, and the intraclonal mutational rate is clearly below that exhibited during diversification of the antigen receptor in normal B cells. However, there is evidence for a low rate of intraclonal mutation in CLL, even in the 'unmutated' subset with 498% homology to GL sequence. 4 Among these cases, only 1/5 had variants repeated in 41 clone. While lack of repeats prevents confirmation of the reality of the mutations, it might be expected if mutational events are relatively random and of low frequency. An intriguing single case of splenic marginal zone lymphoma with 499% homology also showed suggestive evidence for intraclonal heterogeneity. 5 Recently, we have analyzed V H -genes in hairy cell leukemia (HCL). These tumors commonly express multiple isotypes and the majority have undergone somatic mutation in all isotype variants. 6 The new finding that 2/13 HCL cases displayed germline tumor-derived V H -genes (Forconi F et al, submitted) prompted the question whether a further 3/13 cases with 498% homology were actually unmutated. Tumor V H transcripts were identified by established RT-PCR and cloning procedures described previously. 6 Full sequence transcripts were analyzed and shared the same CDR3 in multiple clones. Cases 103 and 163 ( Figure 1) revealed V H -genes with 98.6 and 98.2% homology to the closest germline allele, V 4-31 and V 1-02 , respectively. 6 Case 330 displayed 98.6% homology to the V 2-05 gene.
Intraclonal heterogeneity among different clones was distinguished from Taq infidelity by an increased frequency as compared to Taq error rate. Strikingly, for all the three cases, analysis of multiple clones clearly showed identical nucleotide changes repeated in either one or more isotype variants (Figure 1 ). This indicates that there has been ongoing mutational activity in the tumor clone, even in the absence of a high level of mutations common to all clones. In contrast to 'unmutated' CLL, several mutations are shared between clones, both confirming their reality and indicating the outgrowth of related clones.
Our conclusion therefore is that a low level of somatic mutation can occur in B-cell tumors and may be misinterpreted as polymorphisms, by using a 98% cutoff. As we have shown here, one way to overcome this difficulty is to demonstrate intraclonal heterogeneity, as indicative of ongoing mutations. Identical mutations repeated in different clones confirm their reality, but may only be evident in tumors such as HCL, which combine early mutational events with the outgrowth of variants. However, not all 'unmutated' cases continue to accumulate intraclonal base changes, indicating that this group of HCL can now be divided into two subsets: the first minor subset being completely unmutated, and the second with a low level of shared mutations (498% homology) and continuing mutational activity. This addition to the hierarchy of somatic mutational status may also be applicable to other B-cell tumors.
Low levels of mutations can occur independently of T-cell help, especially in response to multivalent antigens. 7 'Unmutated' B-cell tumors, with low mutational load, could derive from this stage. It is possible that there are two tiers of somatic mutational activity influenced by the level of antigen stimulation, 8 and by the availability of T-cell help at the site occupied. In terms of prognosis, the clear distinction between cases with 498% or o98% homology indicates that, at least in CLL, there is a behavioral distinction between B cells at the two points of transformation. However, it is likely that additional subsets will be defined within these broad groups, and the correlation between emerging biological features and clinical progression will be of interest. Intraclonal heterogeneity in HCL V H -genes with 498% homology to the germline gene reveals a somatically mutated status. Tumor V H transcripts were identified by established RT-PCR and cloning procedures described previously. 6 Transcripts shared the same CDR3 in multiple clones. Intraclonal heterogeneity among different clones was distinguished from Taq infidelity by an increased frequency as compared to the Taq error rate, and by the finding of the same mutations in more than one clone and/or in different PCRs. Partial nucleotide sequences of tumor V Hgenes are shown aligned to the germ line. Isotype transcripts, with the number of identical clones sequenced in parentheses, are delineated. For each case, the predominant clone (top line) and clones with additional mutations are shown. Only clones with mutations shared with at least another clone are represented. Letters above the germline sequence indicate amino acids. Replacements are indicated in capital, underneath each mutation. A variant mutation pattern was observed in different tumor isotypes (cases 103 and 163) or in IgM alone (case 330). Each of the 3/3 cases had additional mutations occurring at a frequency higher than the Taq error rate.
